Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30430032 | 0.87 | MLYCD (0.45) | MLYCDHPGDCLK1DYRK1ADYRK1B | |
| SCHEMBL13002606 | 0.87 | MLYCD (0.45) | MLYCDHPGDCLK1DYRK1ADYRK1B | |
| SCHEMBL4843412 | 0.84 | MLYCD (0.49) | MLYCDHPGDCLK1DYRK1ADYRK1B | |
| SCHEMBL2787613 | 0.83 | ESR1 (0.47) | MLYCDHPGDCLK1DYRK1ADYRK1B | |
| SCHEMBL3818058 | 0.82 | MTOR (0.47) | MTORHPGDALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL6988786 | 0.82 | MLYCD (0.44) | MLYCDHPGDCLK1DYRK1ADYRK1B | |
| SCHEMBL5775166 | 0.82 | MLYCD (0.48) | MLYCDHPGDCLK1DYRK1ADYRK1B | |
| SCHEMBL2236490 | 0.80 | MAPT (0.58) | MLYCDHPGDCLK1DYRK1ADYRK1B | |
| SCHEMBL8988251 | 0.80 | MLYCD (0.45) | MLYCDHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL30480721 | 0.80 | MAPT (0.58) | MLYCDHPGDCLK1DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT,INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | ACELOT, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | MLYCD 3623/4885MTOR 2906/4885HPGD 3424/4885 |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | APP, PSEN2, PSEN1 | MLYCD 3742/4885MTOR 1798/4885HPGD 3593/4885 |
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | MLYCD 3764/4885MTOR 1866/4885HPGD 424/4885 |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | MLYCD 3288/4885MTOR 321/4885HPGD 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.